Don't Sell Celgene

Despite a big rally, the biotech giant's stock can further reward investors, due in part to two recent approvals.

Just over a month ago, Celgene Chairman and CEO Robert Hugin stood before a gathering of investors and analysts at J.P. Morgan's annual health-care conference and predicted that the biotech giant's top line could double by 2017 as it benefits from the arrival of new drugs and efforts to expand uses for older ones.

And based on recent news, it seems that Celgene (ticker: CELG) is on its way toward meeting those goals.